

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

PROFIT WARNING

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2025 (the “**Management Accounts**”), the Group expects to record a loss in the range between HK\$450 million and HK\$480 million, as compared to a profit for the six months ended 30 September 2024. The expected turnaround from profit to loss in the current period was primarily attributable to an unrealised loss recognised on the fair value of the Group’s investments in convertible bonds, while a gain arising from the fair value change of the same item was recorded in the corresponding period of 2024. Such unrealised loss is non-cash in nature. During the current period, the Group’s operating segments have maintained a steady performance.

The Company is still in the process of preparing the interim results of the Group for the six months ended 30 September 2025, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have yet to be confirmed. The unaudited consolidated interim results of the Group for the six months ended 30 September 2025 are expected to be published before the end of November 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 20 November 2025

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.

* For identification purpose only